The Health Ministry has approved the use of the AstraZeneca vaccine following primary analysis of Phase III clinical trials from the United Kingdom, Brazil and South Africa.
The trials confirmed that it is safe and effective at preventing Covid-19, with no severe cases and no hospitalisations, more than 22 days after the first dose, according to a press release from AstraZeneca Vietnam.
AstraZeneca Vietnam and the Vietnam Vaccine Joint Stock Company (VNVC) will work together to supply 30 million doses in the country, starting mid-year.
A representative from VNVC said that the company has completed negotiations on the deal with AstraZeneca – a global biopharmaceutical business from the UK.
Supply director of VNVC Vu Thi Thu Ha said her company has made the best preparations to receive the vaccines and give injections to residents.
The analysis result of the vaccine was published as a preprint in The Lancet.
Results demonstrated vaccine efficacy of 76% after the first dose, with protection maintained to the second dose.
With an inter-dose interval of 12 weeks or more, vaccine efficacy increased to 82%.
The analysis also showed the potential for the vaccine to reduce asymptomatic transmission of the virus, based on weekly swabs obtained from volunteers in the UK trial.
The data showed that PCR positive readings were reduced by 67% after a single dose, and 50% after the two-dose regimen, supporting a substantial impact on transmission of the virus.
The primary analysis for efficacy was based on 17,177 participants with 332 symptomatic cases from the Phase III UK, Brazil and South Africa trials led by Oxford University and AstraZeneca, a further 201 cases than previously reported.
“This primary analysis reconfirms that our vaccine prevents severe disease and keeps people out of hospitalm” said Mene Pangalos, executive vice-president of biopharmaceuticals R&D at AstraZeneca.
“In addition, extending the dosing interval not only boosts the vaccine’s efficacy, but also enables more people to be vaccinated upfront.” — Vietnam News/ANN